PD-1 monoclonal antibody is named as a drug or biological intervention in 15 clinical trials in our China trial register, 11 of which are recruiting. Lead sponsors include Sichuan Baili Pharmaceutical Co., Ltd. (6), Sixth Affiliated Hospital, Sun Yat-sen University (2) and Jun Huang (2). Registered phases: Phase 2, Phase 3, Observational and Phase 4. Conditions studied include Nasopharyngeal Carcinoma (NPC); Gastric Cancer; Colorectal Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Nasopharyngeal Carcinoma (NPC) | 2 |
| Gastric Cancer | 2 |
| Colorectal Cancer | 2 |
| Rectal Adenocarcinoma | 2 |
| High-Risk Cancer | 2 |
| MSS | 2 |
| HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | 1 |
| Esophageal Cancer | 1 |
| GastroEsophageal Cancer | 1 |
| BCLC Stage B Hepatocellular Carcinoma | 1 |
| BCLC Stage C Hepatocellular Carcinoma | 1 |
| Hepatic Arterial Infusion Chemotherapy | 1 |
| Lenvatinib | 1 |
| Liver Metastases | 1 |
| Lung Cancer Non-Small Cell Cancer (NSCLC) | 1 |
| EGFR Activating Mutation | 1 |
| PD-1 Antibody | 1 |
| Colorectal Cancer (CRC) | 1 |
| pMMR/MSS Adenocarcinoma of the Colon or Rectum | 1 |
| Non-small Cell Lung Cancer | 1 |
| Nasopharyngeal Carcinoma | 1 |
| Solid Tumor | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| HCC | 1 |
| Nasopharangeal Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 6 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 2 |
| Jun Huang | 2 |
| Shanghai Zhongshan Hospital | 1 |
| First Hospital of China Medical University | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Chen Xiaoping | 1 |
| Sun Yat-sen University | 1 |
| Register | PD-1 monoclonal antibody trials |
|---|---|
| Clinical trials in China | 15 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1 monoclonal antibody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1 monoclonal antibody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.